A preprint posted on Research Square on 31 March 2026 reports the first-in-human trial of VES001, an orally taken small molecule that blocks the receptor sortilin from removing progranulin, the protein that is genetically low in frontotemporal dementia caused by GRN mutations (FTD-GRN). The phase 1a study (ClinicalTrials.gov NCT06226064) was randomised, double blind and placebo controlled: six single-dose cohorts of eight healthy volunteers received 10 mg to 990 mg, and three further cohorts of ten took 180 mg once daily, 180 mg twice daily or 450 mg twice daily for seven days, 78 participants in all. After a week of dosing, progranulin in cerebrospinal fluid rose against placebo by 17.2 per cent (95 per cent confidence interval 7.0 to 28.5) in the 180 mg twice-daily group and by 17.7 per cent (7.4 to 29.0) in the 450 mg twice-daily group, both p less than 0.01; the once-daily regimen showed no significant effect. The authors report no serious adverse events and no dose-limiting toxicity, with headache and fatigue the most common events, described as mild and not dose related. The work is preliminary: it is a preprint that has not completed peer review, several authors work for, hold patents with, or hold shares in the sponsor, Vesper Bio, and the accompanying progranulin rises in rat plasma, spinal fluid and hippocampal fluid are animal data.
The interest lies in what came before. Sortilin binds progranulin and sends it for degradation, so blocking the receptor should leave more progranulin outside the cell. That reasoning was tested at scale with an infused antibody, latozinemab, in the 96-week phase 3 INFRONT-3 trial (NCT04374136). Alector announced on 21 October 2025 that the trial missed its clinical co-primary endpoint, the CDR plus NACC FTLD Sum of Boxes score, in symptomatic participants, while meeting the biomarker co-primary of raised plasma progranulin; fluid biomarkers and volumetric MRI showed no treatment-related effects, and the company later stopped the open-label extension. Raising progranulin, in other words, has already been shown once not to be the same as changing the course of the illness.
VES001 has since been given to people with the mutation but no symptoms. The registry record for SORT-IN-2 (NCT06705192), an open-label, uncontrolled study at Erasmus University Medical Centre in Rotterdam and University College London, lists six asymptomatic GRN carriers taking 360 mg and then 900 mg daily over three months; it started on 12 December 2024 and completed on 5 August 2025. Vesper Bio said in a statement on 31 October 2025 that mean progranulin in cerebrospinal fluid rose by more than 95 per cent from baseline at the higher dose, with dose-dependent increases in plasma and spinal fluid and few adverse events, and that it would prepare a phase 2b/3 trial in symptomatic FTD-GRN. Those figures come from the company and have not yet appeared in a peer-reviewed paper.
No trial has yet tested whether VES001 changes symptoms, imaging or the age at which carriers become unwell. The phase 1a study ran for seven days in healthy volunteers whose progranulin was already normal, and the carrier study had six participants and no comparison group, a design that can show target engagement but cannot show benefit. Whether an oral drug given years before symptoms answers the question INFRONT-3 left open, that is, whether the timing rather than the target was wrong, depends on a trial that has not started.